Therefore, it is possible that, in this study, the SFN-mediated activation of the Nrf2 pathway is only protective against acute challenges such as intermittent hypoglycaemia and not chronic hyperglycaemia, which was established before the SFN treatment began. The gene discussed is NFE2L2; the disease is Hyperglycemia.